Study Stopped
primary goal not achievable
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
1 other identifier
interventional
4
1 country
1
Brief Summary
This study is a randomized prospective clinical trial of women with metastatic breast cancer. The purpose of the study is to test if an intervention of regular physical activity review and physical activity goal setting will allow the subjects to achieve a moderate increase in physical activity of 6,000 steps per week. The physical activity review will consist of weekly telephone call to inquire about symptoms and to set physical activity goals. The study will also look to see if the goal setting intervention will affect the time to progression, change in BMI, and quality of life. Quality of life will be measured by answers to questionnaires provided to subjects at regular intervals during the course of the study. Finally, the study will examine the impact of physical activity on expression of tumor molecular molecules, insulin levels, and estradiol levels. Through an intervention of regular physical activity review and goal setting, the investigators hypothesize that a moderate increase in level of physical activity of 6000 steps per week or more can be obtained by patients with metastatic breast cancer who receive a goal setting intervention. The investigators propose that those who are able to achieve and maintain greater than or equal to 22500 steps per week will demonstrate biologic and molecular differences compared to those who are not able to achieve that level of physical activity. The investigators expect that people who are more active will have longer to progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2012
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 19, 2012
CompletedFirst Posted
Study publicly available on registry
July 31, 2012
CompletedStudy Start
First participant enrolled
December 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2016
CompletedAugust 16, 2016
June 1, 2012
3.1 years
July 19, 2012
August 15, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in physical activity as a result of a goal setting intervention using pedometer data and exercise logs.
To increase physical activity levels by at least 6000 steps/wk over 6 months using a goal setting intervention
Baseline, 2 month, 3 month, 4 month, 5 month, 6 months
Secondary Outcomes (7)
Secondary objectives: Time to progression
baseline, 6 months
Change in Body Mass Index (BMI)
Baseline, 2 month, 3 month, 4 month, 5 month, 6 months
Health related quality of life
baseline, 6 months
Correlative Science outcomes in peripheral blood
baseline, 6 months
Correlative science outcomes in tissue biopsies
baseline, 6 months
- +2 more secondary outcomes
Study Arms (2)
Arm A-Pedometer and Goal setting
EXPERIMENTALPhysical Activity Goal Setting Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log.
ARM B
NO INTERVENTIONPatients receive standard physical activity recommendations and follow up.
Interventions
Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the "Exercise and Breast Cancer" digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them.
Eligibility Criteria
You may qualify if:
- Subjects with measurable per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 and biopsy-able (as determined by Co-Investigator John Gemery, MD) metastatic carcinoma of the breast.
- Physically able to undertake a moderate physical activity program.
- Greater than 4 weeks from any radiation treatments for metastatic disease.
- standard of care biopsy must occur within 30 days of registration.
- Able to follow directions and fill out questionnaires and physical activity diaries in English.
- Willing to consent to biopsies and be randomly assigned to one of two study arms which may or may not include physical activity goal setting.
- Consents to be contacted via phone or internet (see Appendix K).
- No to all questions on Physical Activity Readiness Questionnaire (see appendix A) or approved by primary oncologist or other care provider provider for participation.
- Hb \>10 without transfusion, liver function tests less than 3 times upper limits of normal, normal thyroid-stimulating hormone (TSH), absolute neutrophil count (ANC) \>1500.
- Karnofsky performance status ≥ 80%
- Previous Physical Therapy consultation and treatments acceptable.
- Participation in other trials acceptable.
- CNS disease that is treated and stable by MRI for at least 6 months
You may not qualify if:
- Patients less than 18 years of age.
- Patients unable to give informed consent indicating they are aware of the investigational nature of this treatment, prior to entry into the study.
- Pregnant or nursing women.
- Patients with any untreated (CNS) disease.
- Patients with other active cancers requiring treatment.
- Patients with clotting or bleeding disorder precluding biopsy.
- Patients with significant cardiovascular disease, including uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months or serious cardiac arrhythmias will be excluded.
- Current use of supplements containing conjugated linoleic acid, or use within the 30 days preceding registration.
- Persons with a known diagnosis of diabetes are not eligible. Prior use of metformin allowable if previously enrolled on MA.32 trial as part of their adjuvant therapy for early stage breast cancer.
- Persons of male gender.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mary Chamberlin, MD
Dartmouth-Hitchcock Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 19, 2012
First Posted
July 31, 2012
Study Start
December 1, 2012
Primary Completion
January 1, 2016
Study Completion
January 1, 2016
Last Updated
August 16, 2016
Record last verified: 2012-06